OOIR: Observatory of International Research

Papers

(The H4-Index of Annals of Allergy Asthma & Immunology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Atopic dermatitis in the pediatric population	234
New treatments in atopic dermatitis	136
The infectious complications of atopic dermatitis	96
Asthma and the social determinants of health	91
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma	75
Anaphylaxis: A 2023 practice parameter update	63
Potential association of mast cells with coronavirus disease 2019	60
The COVID-19 pandemic	57
Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis	57
New and emerging treatments for inflammatory itch	53
Social media and its impact on health care	52
Secondary immunodeficiencies	50
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis	49
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Ins	47
Hereditary alpha-tryptasemia in 101 patients with mast cell activation–related symptomatology including anaphylaxis	47
The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection	44
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions	44
Real-world persistence with dupilumab among adults with atopic dermatitis	43
Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions	39
Biologics in eosinophilic gastrointestinal diseases	38
A review of contact dermatitis	37
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY	37
Clinical guidance for the use of dupilumab in eosinophilic esophagitis	37
Assessment and feedback methods in competency-based medical education	36
Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018	35

Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in	35
Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines	34
Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use	34
Bleach baths for atopic dermatitis	34
Prenatal PM2.5 exposure and vitamin D–associated early persistent atopic dermatitis via placental methylation	33
Food protein-induced enterocolitis syndrome epidemiology	33
Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019	33
Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma	32
Clinical relevance of inherited genetic differences in human tryptases	32
Skin tape sampling technique identifies proinflammatory cytokines in atopic dermatitis skin	32
A scoping review of the caregiver burden of pediatric food allergy	32